Monitoring of patients given second-generation antipsychotic agents [2]

Psychiatric Services

Volumn 57, Issue 7, 2006, Pages 1045-1046

  Olson, Kari L ^a,b   Delate, Thomas ^a   Duagn, Daniel J ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; CARDIOVASCULAR RISK; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LETTER; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MENTAL PATIENT; PATIENT CARE; PATIENT MONITORING; PRESCRIPTION; PSYCHOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENCHMARKING; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; COLORADO; DRUG MONITORING; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES;

EID: 33745831960     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.57.7.1045-a     Document Type: Letter

References (3)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologiste, et al: Consensus development conference on ahtipsychotic drugs and obesity arid diabetes. Diabetes Care 27:596-601, 2004
2. Allison DB, Mentore JL, Moonseong H, et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156:1686-1696, 1999
3. Lindenmayer JP, Czobor P, Volavka J, et al: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry 160:290-296, 2003